High-Quality GPCR Antibody Discovery Using Full-Length Nanodisc GPCR Proteins and Single B-Cell Technology

GPCRs represent one of the most important yet technically challenging classes of drug targets, largely due to difficulties in producing stable, native like antigens and generating high-quality antibodies. In this presentation, Dr. Donghui Ma will share DIMA Biotechnology’s integrated strategy for GPCR antibody discovery, combining proprietary full-length Nanodisc GPCR protein platforms with single B-cell cloning technology.

DIMA’s Nanodisc platforms enable the production of functional, full-length GPCR proteins that preserve native conformation and signaling activity. These proteins are used directly as antigens for antibody discovery, significantly improving antibody specificity, affinity, and functional relevance.

When paired with single B-cell technology, this approach allows rapid isolation of high quality monoclonal antibodies against challenging GPCR targets.

The presentation will highlight real-world case studies, key technical considerations, and data demonstrating how this workflow accelerates GPCR antibody generation with high success rates.

Attendees will gain practical insights into overcoming GPCR antibody discovery bottlenecks and enabling downstream applications in research, diagnostics, and drug development.

Learning Objectives:

1. Understand the key challenges in GPCR antigen preparation and antibody discovery and how Nanodisc-based full-length GPCR proteins address these limitations.

2. Evaluate the advantages of combining native-like GPCR antigens with single B-cell cloning for generating high-quality, functional antibodies.

3. Apply best practices and strategic considerations for accelerating GPCR antibody discovery with higher success rates and shorter timelines.